Skip to content

Fluvastatin Sodium

FDA-approved product (capsule, oral), marketed as Fluvastatin Sodium, Lescol, Lescol Xl.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Fluvastatin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Familial hypercholesterolemia
  • Hypercholesterolemia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Hmg coa reductase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA47.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli27.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae18.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fluvastatin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Erythrocyte-bound Apolipoprotein B After Withdrawal of Statin Therapy

    NCT01634906 · start 2012-07

    Registered record
    Registry ID
    NCT01634906
    Conditions
    Hyperlipidemia; Atherosclerosis
    Interventions
    Temporary discontinuation of statin therapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-07
    Completion
    2013-03
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperlipidemia; Atherosclerosis
    InterventionTemporary discontinuation of statin therapy
    PhaseNot applicable
    Registry statusCompleted
  • High Potency Statins and the Risk of Diabetes

    NCT02518503 · start 2012-07

    Registered record
    Registry ID
    NCT02518503
    Conditions
    Diabetes Mellitus, Type 2; Cardiovascular Disease
    Interventions
    Rosuvastatin (≥10 mg); Atorvastatin (≥20 mg); Simvastatin (≥40 mg); Fluvastatin; Pravastatin; Lovastatin; Rosuvastatin (<10mg); Atorvastatin (<20mg); Simvastatin (<40 mg)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-07
    Completion
    2013-02
    Enrolment
    136,966

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2; Cardiovascular Disease
    InterventionRosuvastatin (≥10 mg); Atorvastatin (≥20 mg); Simvastatin (≥40 mg); Fluvastatin +5 more
    PhaseNot recorded
    Registry statusCompleted
  • The Rosuvastatin In TrAnsplant Recipients Study

    NCT01524601 · start 2012-02

    Registered record
    Registry ID
    NCT01524601
    Conditions
    Disorder Related to Renal Transplantation; Hypercholesterolemia
    Interventions
    Rosuvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-02
    Completion
    2012-10
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDisorder Related to Renal Transplantation; Hypercholesterolemia
    InterventionRosuvastatin
    PhasePhase 4
    Registry statusCompleted
  • Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

    NCT01551173 · start 2012-01

    Registered record
    Registry ID
    NCT01551173
    Conditions
    Lipid Metabolism Disorders
    Interventions
    Fluvastatin sodium
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-01
    Completion
    2013-05
    Enrolment
    436

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLipid Metabolism Disorders
    InterventionFluvastatin sodium
    PhasePhase 4
    Registry statusCompleted
  • A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

    NCT01492361 · start 2011-11

    Registered record
    Registry ID
    NCT01492361
    Conditions
    Cardiovascular Diseases
    Interventions
    AMR101; Placebo; Statin therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-11
    Completion
    2018-05
    Enrolment
    8,179

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases
    InterventionAMR101; Placebo; Statin therapy
    PhasePhase 3
    Registry statusCompleted
  • High Potency Statins and Acute Kidney Injury

    NCT02518516 · start 2011-01

    Registered record
    Registry ID
    NCT02518516
    Conditions
    Hypercholesterolemia
    Interventions
    Rosuvastatin (≥10 mg); Atorvastatin (≥20 mg); Simvastatin (≥40 mg); Fluvastatin; Pravastatin; Lovastatin; Atorvastatin (<20mg); Simvastatin (<40 mg)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-01
    Completion
    2013-01
    Enrolment
    2,067,639

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypercholesterolemia
    InterventionRosuvastatin (≥10 mg); Atorvastatin (≥20 mg); Simvastatin (≥40 mg); Fluvastatin +4 more
    PhaseNot recorded
    Registry statusCompleted
  • Evaluation of Patients With Statin Myopathy Using an N of 1 Trial Design

    NCT01259791 · start 2010-09

    Registered record
    Registry ID
    NCT01259791
    Conditions
    Statin Myopathy
    Interventions
    Individual-specific statin causing myopathy; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-09
    Completion
    2013-08
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStatin Myopathy
    InterventionIndividual-specific statin causing myopathy; Placebo
    PhaseNot applicable
    Registry statusCompleted
  • Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing PCI

    NCT01293097 · start 2010-06

    Registered record
    Registry ID
    NCT01293097
    Conditions
    Non-ST Segment Elevation Myocardial Infarction; Unstable Angina Pectoris; Stable Angina Pectoris
    Interventions
    Atorvastatin; Statin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-06
    Completion
    2011-10
    Enrolment
    2,884

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-ST Segment Elevation Myocardial Infarction; Unstable Angina Pectoris; Stable Angina Pectoris
    InterventionAtorvastatin; Statin
    PhasePhase 4
    Registry statusCompleted
  • A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C

    NCT00814606 · start 2010-02

    Registered record
    Registry ID
    NCT00814606
    Conditions
    Hepatitis C; Hepatitis C Virus
    Interventions
    Fluvastatin; Peginterferon alfa2a; ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2010-02
    Completion
    2010-10
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C; Hepatitis C Virus
    InterventionFluvastatin; Peginterferon alfa2a; ribavirin
    PhasePhase 2
    Registry statusWithdrawn
  • Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

    NCT01047501 · start 2009-12

    Registered record
    Registry ID
    NCT01047501
    Conditions
    Hypertriglyceridemia
    Interventions
    AMR101 (ethyl icosapentate) - 4 g/day; AMR101 (ethyl icosapentate) - 2 g/day; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-12
    Completion
    2011-02
    Enrolment
    702

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertriglyceridemia
    InterventionAMR101 (ethyl icosapentate) - 4 g/day; AMR101 (ethyl icosapentate) - 2 g/day; Placebo
    PhasePhase 3
    Registry statusCompleted
  • Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL

    NCT01047683 · start 2009-12

    Registered record
    Registry ID
    NCT01047683
    Conditions
    Hypertriglyceridemia
    Interventions
    AMR101 (ethyl icosapentate) - 4 g/day; AMR101 (ethyl icosapentate) - 2 g/day; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-12
    Completion
    2011-07
    Enrolment
    229

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertriglyceridemia
    InterventionAMR101 (ethyl icosapentate) - 4 g/day; AMR101 (ethyl icosapentate) - 2 g/day; Placebo
    PhasePhase 3
    Registry statusCompleted
  • Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients

    NCT00674297 · start 2008-05

    Registered record
    Registry ID
    NCT00674297
    Conditions
    Antiphospholipid Syndrome
    Interventions
    Fluvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-05
    Completion
    2013-02
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntiphospholipid Syndrome
    InterventionFluvastatin
    PhasePhase 2
    Registry statusCompleted
  • Observational Study of Approaches to Lipid-Lowering Therapy in Russian Patients With Coronary Heart Disease <<Treat to Goal>> (Study P05464)

    NCT00730132 · start 2008-01

    Registered record
    Registry ID
    NCT00730132
    Conditions
    Coronary Heart Disease; Hypercholesterolemia
    Interventions
    Ezetimibe; Statin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-01
    Completion
    2009-08
    Enrolment
    712

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Heart Disease; Hypercholesterolemia
    InterventionEzetimibe; Statin
    PhaseNot recorded
    Registry statusCompleted
  • Observational Study On Compliance Of Statin Treatment Of Patients With High Blood Cholesterol Levels

    NCT00673660 · start 2007-10

    Registered record
    Registry ID
    NCT00673660
    Conditions
    Dyslipidemia
    Interventions
    Patient Compliance
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2007-10
    Completion
    2009-10
    Enrolment
    375

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDyslipidemia
    InterventionPatient Compliance
    PhaseNot recorded
    Registry statusCompleted
  • Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin

    NCT00487318 · start 2007-06

    Registered record
    Registry ID
    NCT00487318
    Conditions
    Chronic Hepatitis C
    Interventions
    standard of care; fluvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-06
    Completion
    2010-10
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    Interventionstandard of care; fluvastatin
    PhasePhase 2
    Registry statusCompleted